Castle Biosciences, Inc. $CSTL Stock Holdings Lowered by Stephens Inc. AR

Stephens Inc. AR decreased its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 16.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,386 shares of the company’s stock after selling 2,253 shares during the quarter. Stephens Inc. AR’s holdings in Castle Biosciences were worth $233,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Harbour Investments Inc. purchased a new position in Castle Biosciences during the 1st quarter worth approximately $50,000. Jones Financial Companies Lllp boosted its position in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the period. Amundi grew its holdings in shares of Castle Biosciences by 15,811.5% during the first quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after buying an additional 4,111 shares in the last quarter. CWM LLC raised its position in Castle Biosciences by 835.0% during the first quarter. CWM LLC now owns 4,142 shares of the company’s stock valued at $83,000 after buying an additional 3,699 shares during the period. Finally, Teacher Retirement System of Texas lifted its stake in Castle Biosciences by 9.6% in the 1st quarter. Teacher Retirement System of Texas now owns 10,383 shares of the company’s stock worth $208,000 after acquiring an additional 908 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $23.96 on Tuesday. The business has a 50 day simple moving average of $22.79 and a 200 day simple moving average of $19.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.69. The company has a market capitalization of $695.08 million, a PE ratio of -68.46 and a beta of 1.13. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.66. The firm had revenue of $86.18 million for the quarter, compared to analysts’ expectations of $71.53 million. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%. Castle Biosciences has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Derek J. Maetzold sold 1,339 shares of Castle Biosciences stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $22.44, for a total value of $30,047.16. Following the completion of the transaction, the insider owned 62,988 shares in the company, valued at approximately $1,413,450.72. The trade was a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Canaccord Genuity Group reissued a “buy” rating and issued a $37.00 price target on shares of Castle Biosciences in a research note on Tuesday, September 9th. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Castle Biosciences in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.